3 min read

Abveris Announces Multi-Target, Multi-Year Therapeutic Antibody Discovery Collaboration with Prometheus Biosciences

By Gary Ng on 11/11/21 8:58 AM

See the announcement on PR Newswire


Canton, MA, USA--(San Diego, CA, USA)--Abveris, a leader in antibody drug discovery, today announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris’s role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases.

Under this partnership agreement, Abveris will utilize its proprietary DiversimAbTM hyperimmune mouse technology in combination with humanized mice to develop antibodies against several novel therapeutic targets. Capitalizing on the use of its industry-leading rapid B cell screening platform powered by the Berkeley Lights Beacon®, Abveris will identify promising antibody drug candidates via function-forward, high-resolution screening under expedited timelines.

“We are proud to expand our existing partnership with the team at Prometheus Biosciences to help bring novel biologics to the autoimmune space,” commented Tracey Mullen, Chief Executive Officer at Abveris. “The Abveris antibody discovery platform, combined with the drug development capabilities of the Prometheus team, will provide promising therapeutics to patients around the world.”

“Our team has been impressed by Abveris’ exceptional level of scientific expertise and ability to discover and deliver antibodies with the potential to translate into therapeutic candidates,” said Olivier Laurent, Ph.D., Chief Technology Officer of Prometheus. “We look forward to continuing our partnership with Abveris to aid in our portfolio expansion with the common goal of bringing transformational therapies to patients.”

About PROMETHEUS BIOSCIENCES:

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD). The Company’s precision medicine platform, Prometheus360, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody (mAb) for the treatment of the two most common forms of IBD, Ulcerative Colitis (UC) and Crohn’s Disease (CD). The Company has initiated enrollment in a Phase 2 trial in UC patients and a Phase 2a trial in CD patients, each utilizing a genetic-based companion diagnostic designed to identify patients more likely to respond to PRA023.

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders. Additional information about Abveris is available at www.ABVERIS.com.

Contacts
Garren Hilow
Chief Business Officer
ghilow@abveris.com 


Abveris Logo_no_tag-1

 

Topics: Insider Press Releases
3 min read

Abveris and Abilita Bio Announce Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets

By Csaba Pazmany on 8/24/21 10:36 AM

See the announcement on PR Newswire

 – The research collaboration will leverage synergies between the Abilita Bio EMP™ and Abveris DiversimAb™ platforms to identify novel therapeutic antibodies that target historically intractable GPCRs for the treatment of cancer


Canton, MA, USA--(San Diego, CA, USA)--Abveris, Inc. (“Abveris”) and Abilita Bio, Inc. (“Abilita”), both privately held biotechnology companies, announce a joint research collaboration that will leverage the synergies between their platforms to enable the discovery of novel antibodies targeting key GPCRs within the tumor immune microenvironment.

The difficulty in discovering therapeutic antibodies targeting multi-span membrane proteins (MMPs) such as GPCRs is well known to the field and has resulted in a massive R&D gap. The crux lies in the deep unmet need for technologies that can overcome the poor antigenicity and weak immunogenicity associated with MMP antigens. This challenge requires a two-pronged approach that can simultaneously improve the presentation of the properly folded target protein to the immune system and augment the immune response. This collaboration strategically combines cutting-edge platforms that can address the challenge from both sides and has the potential to set a new standard in the field.

Abilita Bio LOGO_1_smaller (1)

Abilita’s EMP™ evolution technology was developed specifically to overcome the challenges associated with high-quality antigen production that have historically hampered antibody discovery efforts. EMP™ antigens, exhibiting unparalleled conformational homogeneity and stability, will be used by Abveris to immunize their proprietary DiversimAb™ mice that have been engineered to overcome the tolerance limitations traditionally experienced with highly conserved proteins while maximizing epitope coverage and hit diversity. The combination of unsurpassed antigen quality and the maximum immune response is anticipated to result in diverse panels of antibodies against even the toughest MMP targets.

“We are excited to launch this joint drug discovery effort with one of the leading innovators in antibody discovery,” said Abilita Bio’s CEO, Mauro Mileni. “The combination of our two platforms makes perfect sense and presents a tremendous opportunity to drive the discovery of novel therapeutic antibodies against tough targets, where traditional discovery efforts have struggled to make headway.”

“Successful antibody discovery against the new wave of therapeutic targets requires continued integration of innovative and sophisticated new technologies,” commented Tracey Mullen, the CEO of Abveris. “The team at Abilita Bio has developed an exciting technology, and when paired with the DiversimAb platform, it promises to redefine the way we approach these targets. We are thrilled to be working with their team of impassioned scientists to provide essential solutions for rapid clinical advancement of cancer therapeutics.”

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders. Additional information about Abveris is available at www.ABVERIS.com.

About abilita Bio:

Abilita Bio, Inc. is a privately held, innovation-driven biotechnology company focused on enabling the discovery and development of drugs targeting challenging human membrane proteins with high medical impact, such as GPCRs, ion channels, and transporters. Abilita Bio’s EMP™ platform fuels research collaborations with pharmaceutical and biotech partners, but also the company’s internal drug discovery pipeline focused on treating cancer and chronic pain. For further information on Abilita Bio, please visit http://www.abilitabio.com/.

Contacts

Csaba Pazmany
Director of Business Development
cpazmany@abveris.com 
(339) 502-4918

Abveris Logo_no_tag-1

 

Topics: Insider Press Releases
3 min read

Abveris Announces Partnership with Foundery Innovations to Develop Therapeutics to Advance Immunotherapy

By Ryan Kelly on 7/21/21 11:16 AM

See the announcement on PR Newswire


Canton, MA, USA--(San Francisco, CA, USA)--Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Foundery Innovations, Inc. (“Foundery Innovations”) for the discovery of monoclonal antibodies to support the development of novel biotherapeutic drugs. Under the terms of the agreement, Abveris will utilize its proprietary DiversimAbTM platform in combination with its next-generation rapid B cell screening platform, powered by the Berkeley Lights Beacon®, to identify antibody drug candidates targeting antigens nominated by Foundery Innovations. The DiversimAb platform is propelled by a genetically engineered hyperimmune mouse family for maximum epitopic diversity and advantageous IP opportunities.

Foundery Innovations Logo_20210720

“The team at Foundery Innovations is positioned to redefine immunotherapy with a strong portfolio of tractable targets,” commented Tracey Mullen, Chief Executive Officer of Abveris. “Partnership with Abveris provides advanced, best-in-class antibody discovery through high-resolution single B cell screening, which will enable rapid clinical advancement for these novel therapeutic products.”

“The enthusiasm, expertise, and track record of the Abveris team was evident from our first meeting. We were particularly impressed by Abveris’ interest in seeking optimal screening strategies for our challenging targets. Foundery looks forward to a productive and long-term partnership with Abveris” said Foundery CEO, Michel Streuli.

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders. Additional information about Abveris is available at www.ABVERIS.com.

About Foundery innovations:

Foundery Innovations is a San Francisco-based biotechnology studio and a novel scientist-driven enterprise focused on generating cutting-edge immunotherapeutics. Foundery validates and develops early drug concepts and produces advanced development candidate packages in collaboration with academic investigators that can then be spun out into independent companies or out-licensed to industry partners for clinical development.

Contacts

Ryan Kelly
Director of Business Development
rkelly@abveris.com 
(339) 502-4458

Abveris Logo_no_tag-1

 

Topics: Insider Press Releases
3 min read

How a function-forward B Cell workflow saves Resources and Time

By Gary Ng on 7/1/21 1:07 PM

Antibody discovery works best when high-throughput, high-resolution screening tools exist to quickly identify antibodies with desired binding and functional properties. Limitations on screening speed and depth have created long-standing challenges for antibody discovery scientists, forcing difficult prioritization choices during a step-wise antibody selection process that constrains the quantity and diversity of clones identified that fit the desired screening profile. The inability to perform deep, function-forward screening slows the pace of discovery, adds to project budgets, and increases the risk of project failure due to the length of time required to get a full understanding of the clones on hand.

Single B cell screening technology has promised to increase the throughput of antibody discovery since it first emerged two decades ago. Until recently, however, major commercial B cell screening methodologies have suffered from limited screening resolution that traps users into the same "step-wise" antibody selection process as other technologies, limiting users to basic binding screens with few recombinant reagents (or, with more advanced users, maybe a couple of cell lines). With most commercially available B cell screening technologies, antibody discovery scientists still must select dozens or hundreds of clones to advance to recombinant expression, even though they haven't yet been appropriately triaged for specificity and function. Higher-resolution B cell screening technology promises to limit wasted time and resources by increasing the amount of actionable data scientists have to make decisions on which clones to advance forward for additional testing, saving time and budget.

Abveris' Berkeley Lights Beacon-based single B cell screening platform enables rapid screening and identification of functional antibodies (picture below). This function-forward single B cell workflow can screen 10Ks to 100Ks of antibodies with 4x the resolution of other B cell screening technologies on the market in ONE day. Using the Beacon, our antibody discovery experts exhaustively screen each and every B cell for binding and function using an arsenal of cell-based and bead-based assay formats to rapidly focus on the most promising antibody candidates before the completion of a single day of screening. High-resolution screening data better inform decisions on which clones to advance to the next stage, resulting in significant overall cost and time savings for the antibody discovery process. In conjunction with our DiversimAb technology, this workflow is poised to be a powerhouse for the discovery of diverse functional hits against challenging targets, based on the broadened epitopic and sequence diversity of DiversimAb antibodies.

During a recent webinar of "Accelerated Discovery of Functionally Relevant Antibodies Leveraging Broadened Epitopic Diversity And Single B Cell Screening " our CEO, Tracey Mullen presents a case study from a therapeutic mAb discovery campaign. In this campaign, our DiversimAb hyperimmune mice and Beacon B cell screening platform are combined to rapidly identify a panel of fully validated, highly specific ligand-blocking antibodies in just over two months.

To learn more about the accelerated discovery services we provide to our partners, please visit our technical resource page.

ABVERIS B CELL WORKFLOW ENHANCES COST EFFICIENCY

 

Topics: Insider Press Releases
4 min read

Abveris Deploys Second Berkeley Lights Beacon® System to Expand Single B Cell Antibody Discovery Capacity

By Gary Ng on 4/22/21 10:00 AM

See the announcement on PR Newswire


 

CANTON, Mass., April 22, 2021 – Abveris, Inc., Boston’s leader in antibody discovery services, today announced the deployment of a second Berkeley Lights, Inc. Beacon® optofluidic system to enable expansion of the Abveris antibody discovery offering.

 

The Abveris Single B Cell Antibody Discovery workflow was first announced in 2019 with the acquisition of the initial Beacon system. In combination with DiversimAb™ hyperimmune mice and/or industry-leading humanized mice, this workflow provides best-in-class antibody discovery solutions to a rapidly growing partner base in the biopharma industry. Over the last two years, Abveris has successfully delivered panels of fully characterized lead antibody candidates for over 30 discovery programs using the Berkeley Lights platform, including 21 campaigns targeting cell surface receptors.

 

The introduction of a second Beacon system to the Abveris workflow enables increased throughput for campaigns requiring larger panels of candidate antibodies. Additionally, it improves the screening capacity for workflows necessitating complex, high-resolution functional screens while providing additional opportunities for continued innovation of new capabilities on the instrument. As a result of experience and added capacity, Abveris is offering flexible business terms, including success-based structures to align organizational incentives.

 

“We have spent the last two years prioritizing scientific innovation on the Beacon system and we have been pleased with the results,” commented Colby Souders, Chief Scientific Officer at Abveris. “Incorporating a second Beacon system will allow us to accelerate this innovation and continue to develop additional techniques for high-content single cell interrogation. Ultimately, we aim to provide rapid solutions for antibody discovery campaigns that would otherwise be impossible using alternative techniques or technologies.”

 

“We are thrilled to help enable the high-quality results that helped to propel Abveris’ recent rapid growth,” said John Proctor, Ph.D. SVP, Antibody Therapeutics, Berkeley Lights. “As they expand capacity with a second Beacon, we look forward to seeing Abveris further become a leader in rapid antibody discovery against a broad range of targets.”

About Abveris:

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders.

Abveris has delivered successfully on over 100 therapeutic antibody campaigns against cell surface receptors, and three of the programs have successfully proceeded to the clinic.

Additional information about Abveris is available at www.abveris.com.

About Berkeley Lights: 

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

The Berkeley Lights Platform and the Berkeley Lights’ Beacon® and Lightning™ systems and Culture Station™ instrument are FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Contact:

Gary Ng
Director of Marketing
gary@abveris.com

Logo-1

 

Topics: Insider Press Releases
3 min read

Abveris Presents Integrated Antibody Discovery Workflows Targeting the SARS-CoV-2 Spike Protein for COVID-19 Research

By Gary Ng on 3/23/21 10:17 AM

See the announcement on PR Newswire


Canton, MA, USA Abveris, Inc. today announced the release of antibody sequences specific to the SARS-CoV-2 spike (S) protein into the public domain for unrestricted use (https://www.abveris.com/download-anti-sars-cov2-mab-antibody-sequences-campaign). Leveraging Alloy Therapeutic’s ATX-Gx™ human transgenic mouse platform in parallel with genetically engineered DiversimAb™ mice, Abveris completed concurrent antibody discovery campaigns to develop a diverse panel of unique sequences for potential therapeutic and critical reagent use.

To accelerate the workflow and provide high-content data, Abveris incorporated the use of the Berkeley Lights Beacon® for rapid single B cell screening combined with the Carterra LSA® for high-throughput downstream antibody characterization. The resulting panel of high affinity antibodies span multiple epitopes on the S1 domain (the region of the S protein containing the ACE2 receptor binding domain, which is critical for viral infection). Furthermore, a subset of antibodies exhibits complete blockade of S protein binding to ACE2 and therefore have the potential to serve as viral neutralizing antibodies.

“As the fight against COVID-19 continues, there are many innovative organizations that can benefit from access to additional tools. We hope the antibodies and corresponding data presented here will empower advanced research,” commented Tracey Mullen, Chief Executive Office at Abveris. “As experts in antibody discovery and characterization for therapeutic pipelines, we recognize the benefit our antibodies can provide to the scientific community, and we’re grateful for our collaborators at Alloy Therapeutics and Carterra for their support in this philanthropic effort.”

 
About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders. Additional information about Abveris is available at www.abveris.com.

 
About alloy therapeutics: 

Alloy Therapeutics is a biotechnology ecosystem company dedicated to empowering scientists in the relentless pursuit of making better medicines for all. To this end, Alloy seeks to democratize access to foundational drug discovery platforms and services to scientists worldwide. Alloy’s first platform, the ATX-Gx™ mouse platform, is a suite of transgenic mice designed for best-in-class in vivo discovery of fully human monoclonal antibodies. Alloy’s partners include academic scientists, small and medium biotech, and Fortune 50 biopharma. Founded in 2018 and privately funded by visionary investors, Alloy Therapeutics is headquartered in Boston, Massachusetts with European labs in Cambridge, UK. As a reflection of our irrational commitment to the scientific community, 100% of our revenue from platforms and services is reinvested in innovation and supporting access to innovation. To join the revolution, visit alloytx.com or schedule a 15-minute chat with our Founder and CEO at alloytx.com/ceo.

 
Contact:

Gary Ng
Director of Marketing
gary@abveris.com

Logo-1

 

Topics: Insider Press Releases
3 min read

Abveris Named as One of the Best Places to Work in 2021

By Gary Ng on 3/11/21 9:31 AM

See the announcement on PR Newswire


Canton, MA, USAThe Business Intelligence Group today announced that it has awarded Abveris a Best Places to Work award. The organization sought to identify companies that are actively working to improve their own performance through efforts to challenge employees in environments that make work fun and engaging.

“At the heart of Abveris is a team of highly dedicated and collectively motivated individuals withBest work places 2021 a strong passion for advancing science through the use of new and innovative technologies,” commented Tracey Mullen, CEO of Abveris. “Our team is both our biggest asset and primary differentiator. As such, we find it imperative to prioritize the personal and professional growth of every individual employee. We are honored to be recognized as a Best Places to Work winner, and we have our team to thank for this award.”

“Congratulations to Abveris for building an organization focused on employee engagement and performance,” said Maria Jimenez, Chief Nominations Officer of Business Intelligence Group. “This clearly was the most challenging year for many companies, and it is clear this is a great place to work and employee feedback is not only listened to, but acted upon. Congratulations to the entire team.”

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders. Additional information about Abveris is available at www.abveris.com.

About business intelligence group: 

The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry and business award programs, business executives—those with experience and knowledge—judge the programs. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

 

Contacts:

Gary Ng
Director of Marketing
gary@abveris.com

Maria Jimenez
Business Intelligence Group
+1 (909) 529-2737
jmaria@bintelligence.com

Topics: Insider Press Releases
1 min read

Abveris Beer: Back Again!

By Ryan Kelly on 12/23/20 7:36 AM

The Mabinator

MADE BY SCIENTISTS, FOR SCIENTISTS

BEST ENJOYED AFTER A LONG DAY in the lab

We teamed up with our neighbors at Castle Island Brewery to bring you more specialty beer that mAb scientists are sure to love! Our partners were so excited about our mAb Scientist IPA and Six Pack mAbs Lager we shipped over the summer that we decided to do it again!  

INTRODUCING:
THE MAB-INATOR Hoppy Session Ale

This beer is a session ale with killer taste.  Brewed with columbus and citra hops, it pairs well with anything. We're super excited about how it turned out!  We'll be contacting our partners to ship some of this beer out early 2021. 

 
Want to get your hands on the MAB-INATOR?
1) Follow Abveris on LinkedIn (click here)
2) leave an entertaining comment on our MAB-INATOR post. 
We'll select some of the best commenters and send you a 4-pack! 

For our active antibody discovery partners, we'll be reaching out to confirm shipping starting in 2021. 

Topics: Insider Events
2 min read

Abveris Announces Equity-Bearing Antibody Discovery Partnership with Saccharo

By Ryan Kelly on 12/2/20 9:21 AM

See the announcement on PR Newswire


Canton, MA, USA--(San Francisco, CA, USA)--Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Saccharo, Inc. (“Saccharo”) for the discovery of monoclonal antibodies to advance the Saccharo therapeutic pipeline. Under the terms of the agreement, Abveris will utilize its proprietary DiversimAbTM mouse model in combination with its next-generation B cell screening platform, powered by the Berkeley Lights Beacon®, to rapidly discover monoclonal antibodies. In return for discovery services provided, Abveris will receive compensation partially in the form of equity.

“The team at Saccharo has identified a novel druggable target of great potential and we are honored to be working with them to identify candidate antibodies for clinical development,” commented Garren Hilow, Chief Business Officer of Abveris. “By pairing best-in-class discovery tools with our team of impassioned scientists, we believe that we offer Saccharo the best chance of success in discovering and optimizing the biologic they require for clinical advancement.”

Saccharo_logo

"Saccharo is delighted to be working with Abveris. We see Abveris’s scientists, experience, skills and technology platforms as offering the best potential for success,” said Sherry Martin-Moe, PhD, President/CEO and Co-Founder of Saccharo. “Importantly, they have been real partners in understanding the science and developing a sound strategy to produce the best possible antibodies for Saccharo to take to the clinic.”

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

About Saccharo:

Saccharo is a biotech start up in the immuno-shielding oncology space in pursuit of products for a novel polysaccharide target uniquely found on cancer cells only-not on normal cells, that is constant across all stages and types of cancer. The target is involved in a novel immune shielding pathway and serves as a platform for multiple drug modalities. Additional information about Saccharo is available at www.SACCHARO.com.

Contacts for Abveris

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

 

Contact for saccharo:

Sherry Martin-Moe, PhD

President/CEO and Co-Founder

Smartinmoe@saccharo.com

Topics: Insider Press Releases
1 min read

Joint Application Note By Abveris and Berkeley lights

By Gary Ng on 11/2/20 1:59 PM

app-note-thumbnail

Abveris and Berkeley Lights have published a joint application note on Rapid High-Resolution Screening of Plasma B Cells to Identify Antibody Lead Candidates. This document covers a variety of applications and cutting-edge cell-based assays developed by Abveris using Berkeley Lights's Beacon platform. The following contents are discussed in the note: 

  • Deliver anti-idiotypic antibodies with competitive ligand-blocking activity in half the time of a traditional hybridoma screen

  • Discover a diverse panel of rare, high-affinity antibodies that could not be discovered using phage display against an antigen with a completely homologous off-target product

  • Develop an adherent cell-based binding assay that enables discovery of lead candidate sequences against a challenging membrane-bound target in just 29 days

 

 

Download Application Note


Check out all Abveris materials

Topics: Service & Product Updates Single B Cell Screening

Featured